Home › Research › Tau biomarkers
Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease
Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J et al.. Journal of Alzheimer's disease : JAD, 2014-01-01
Topic: Amyloid, tau and blood-test diagnosis
Background Biomarkers in the cerebrospinal fluid (CSF) can track specific pathophysiological pathways underlying Alzheimer's disease (AD). The connection between these biomarkers remains unclear. Objective To study six CSF biomarkers in a clinical cohort of patients with different neurodegenerative conditions.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Alcolea, D., Carmona-Iragui, M., Suárez-Calvet, M., Sánchez-Saudinós, M. B., Sala, I., Antón-Aguirre, S., et al. (2014). Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-140240
Vancouver
Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, et al. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2014. doi:10.3233/jad-140240. PMID: 24820015.
BibTeX
@article{alcolea2014-24820015,
author = {Alcolea, D. and Carmona-Iragui, M. and Suárez-Calvet, M. and Sánchez-Saudinós, M. B. and Sala, I. and Antón-Aguirre, S. and Blesa, R. and Clarimón, J. and others},
title = {{Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2014},
doi = {10.3233/jad-140240},
pmid = {24820015},
url = {https://doi.org/10.3233/jad-140240}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The connection between these biomarkers remains unclear.
- Objective To study six CSF biomarkers in a clinical cohort of patients with different neurodegenerative conditions.
- Methods We measured markers of amyloid-β protein precursor (AβPP) processing (Aβ42, sAβPPβ, β-secretase activity), neuronal damage (total tau, p-tau), and inflammation (YKL-40) in CSF from 194 participants with the following diagnoses: subjective cognitive impairment or non-amnestic mild cognitive impairment (na-SCI, n = 44), amnestic mild cognitive impairment (aMCI, n = 45), dementia of the Alzheimer type (DAT, n = 59), frontotemporal dementia (FTD, n = 22), and 24 cognitively normal controls.
- We compared biomarkers between clinical groups and CSF-profile groups, and we analyzed the correlation between biomarkers.
Why it matters
This study measured six cerebrospinal fluid markers of amyloid processing, neuronal damage, and inflammation in a clinical cohort with different neurodegenerative conditions to explore how these markers relate to each other. It is a biomarker study and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants44
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 44 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 112 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.0 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 3 / 6 | Cited 7.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Alberto Lleó: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universitat Autònoma de Barcelona: institution h-index 782 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24820015) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Tau biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.